Role of pirfenidone in the management of pulmonary fibrosis

References

• LeslieKOMy approach to interstitial lung disease using clinical, radiological and histopathological patternsJ Clin Pathol200962538740119398592
   PubMed Web of Science ®Google Scholar
• TabajGCFernandezCFSabbaghELeslieKOHistopathology of the idiopathic interstitial pneumonias (IIP): a reviewRespirology201520687388325998242
   PubMed Web of Science ®Google Scholar
• American Thoracic SocietyEuropean Respiratory SocietyAmerican Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001Am J Respir Crit Care Med2002165227730411790668
   PubMedGoogle Scholar
• RaghuGCollardHREganJJATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary FibrosisAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementAm J Respir Crit Care Med2011183678882421471066
   PubMed Web of Science ®Google Scholar
• KatzensteinALMukhopadhyaySMyersJLDiagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseasesHum Pathol20083991275129418706349
   PubMed Web of Science ®Google Scholar
• SwigrisJJBrownKKFlahertyKRThe idiopathic interstitial pneumo-nias and connective tissue disease-associated interstitial lung diseaseCurr Rheum Rev201069198
   Google Scholar
• LarsenBTSmithMLElickerBMDiagnostic approach to advanced fibrotic interstitial lung disease: bringing together clinical, radiologic, and histologic cluesArch Pathol Lab Med Epub2016915
   PubMed Web of Science ®Google Scholar
• WalshSLWellsAUDesaiSRMulticentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchy-mal lung disease: a case-cohort studyLancet Respir Med20164755756527180021
   PubMed Web of Science ®Google Scholar
• RaghuGChenSYYehWSIdiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11Lancet Respir Med20142756657224875841
   PubMed Web of Science ®Google Scholar
• American Thoracic SocietyIdiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)Am J Respir Crit Care Med2000112 pt 1646664
   Google Scholar
• SandboNMechanisms of fibrosis in IPFMeyerKCNathanSDIdiopathic Pulmonary FibrosisNew York, NYHumana Press, Springer2014161205
   Google Scholar
• KingTEJrPardoASelmanMIdiopathic pulmonary fibrosisLancet201137898071949196121719092
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research NetworkRaghuGAnstromKJKingTEJrLaskyJAMartinezFJPrednisone, aza-thioprine, and N-acetylcysteine for pulmonary fibrosisN Engl J Med2012366211968197722607134
   PubMed Web of Science ®Google Scholar
• NewtonCABatraKTorrealbaJTelomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressiveEur Respir J20164861710172027540018
   PubMed Web of Science ®Google Scholar
• SeiboldMAWiseALSpeerMCA common MUC5B promoter polymorphism and pulmonary fibrosisN Engl J Med20113641503151221506741
   PubMed Web of Science ®Google Scholar
• HellingBAYangIVEpigenetics in lung fibrosis: from pathobiol-ogy to treatment perspectiveCurr Opin Pulm Med201521545446226176965
   PubMed Web of Science ®Google Scholar
• KingTEJrBradfordWZCastro-BernardiniSA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisN Engl J Med20143702083209224836312
   PubMed Web of Science ®Google Scholar
• RicheldiLdu BoisRMRaghuGINPULSIS Trial InvestigatorsEfficacy and safety of nintedanib in idiopathic pulmonary fibrosisN Engl J Med2014370222071208224836310
   PubMed Web of Science ®Google Scholar
• TourinOSwigrisJJOlsonALIdiopathic pulmonary fibrosis: the epidemiology and natural history of diseaseMeyerKCNathanSDIdiopathic Pulmonary Fibrosis: A Comprehensive Clinical GuideNew York, NYHumana Press, Springer2014934
   Google Scholar
• CaminatiAMadottoFCesanaGContiSHarariSEpidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretationEur Respir Rev20152413743644426324805
   PubMedGoogle Scholar
• LeyBCollardHRKingTEJrClinical course and prediction of survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med201118343144020935110
   PubMed Web of Science ®Google Scholar
• NathanSDShlobinOAWeirNLong-term course and prognosis of idiopathic pulmonary fibrosis in the new millenniumChest2011140122122921729893
   PubMed Web of Science ®Google Scholar
• NathanSDIdiopathic pulmonary fibrosis phenotypesMeyerKCNathanSDIdiopathic Pulmonary Fibrosis: A Comprehensive Clinical GuideNew York, NYHumana Press, Springer2014221238
   Google Scholar
• KingCNathanSDIdentification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseasesCurr Opin Pulm Med20131946647323912191
   PubMed Web of Science ®Google Scholar
• MeyerKCDanoffSKLancasterLHNathanSDManagement of idiopathic pulmonary fibrosis in the elderly patient: addressing key questionsChest2015148124225226149553
   PubMed Web of Science ®Google Scholar
• LeyBRyersonCJVittinghoffEA multidimensional index and staging system for idiopathic pulmonary fibrosisAnn Intern Med20121561068469122586007
   PubMed Web of Science ®Google Scholar
• RyersonCJVittinghoffELeyBPredicting survival across chronic interstitial lung disease: the ILD-GAP modelChest2014145472372824114524
   PubMed Web of Science ®Google Scholar
• LeyBBradfordWZWeyckerDVittinghoffEdu BoisRMCollardHRUnified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosisEur Respir J20154551374138125614172
   PubMed Web of Science ®Google Scholar
• WadhwaAFlahertyKRThe keys to making a confident diagnosis of IPFMeyerKCNathanSDIdiopathic Pulmonary Fibrosis: A Comprehensive Clinical GuideNew York, NYHumana Press, Springer201477101
   Google Scholar
• MeyerKCDiagnosis and management of interstitial lung diseaseTransl Respir Med201424 eCollection 201425505696
   PubMedGoogle Scholar
• FlahertyKRKingTEJrRaghuGIdiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?Am J Respir Crit Care Med200417090491015256390
   PubMed Web of Science ®Google Scholar
• MeyerKCMultidisciplinary discussions and interstitial lung disease diagnosis: how useful is a meeting of the minds?Lancet Respir Med2016452953127180020
   PubMed Web of Science ®Google Scholar
• WillisBCBorokZTGF-beta-induced EMT: mechanisms and implications for fibrotic lung diseaseAm J Physiol Lung Cell Mol Physiol20072933L525L53417631612
   PubMed Web of Science ®Google Scholar
• FernandezIEEickelbergOThe impact of TGF-β on lung fibrosis: from targeting to biomarkersProc Am Thorac Soc20129311111622802283
   PubMedGoogle Scholar
• FroeseARShimboriCBellayePSStretch-induced activation of transforming growth factor-β1 in pulmonary fibrosisAm J Respir Crit Care Med2016194849626771871
   PubMed Web of Science ®Google Scholar
• IyerSNWildJSSchiedtMJHydeDMMargolinSBGiriSNDietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamstersJ Lab Clin Med199512567797857539478
   PubMed Web of Science ®Google Scholar
• IyerSNGurujeyalakshmiGGiriSNEffects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosisJ Pharmacol Exp Ther1999291136737310490926
   PubMed Web of Science ®Google Scholar
• NakayamaSMukaeHSakamotoNPirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblastsLife Sci2008823–421021718093617
   PubMed Web of Science ®Google Scholar
• ConteEGiliEFagoneEFrucianoMIemmoloMVancheriCEffect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblastsEur J Pharm Sci201458131924613900
   PubMed Web of Science ®Google Scholar
• NoblePWAlberaCBradfordWZCAPACITY Study GroupPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsLancet201137797791760176921571362
   PubMed Web of Science ®Google Scholar
• RicheldiLdu BoisRMRaghuGEfficacy and safety of ninte-danib in idiopathic pulmonary fibrosisN Engl J Med2014370222071208224836310
   PubMed Web of Science ®Google Scholar
• TaniguchiHEbinaMKondohYPirfenidone in idiopathic pulmonary fibrosisEur Respir J20103582182919996196
   PubMed Web of Science ®Google Scholar
• NoblePWAlberaCBradfordWZPirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsEur Respir J201647124325326647432
   PubMed Web of Science ®Google Scholar
• OguraTAzumaAInoueYAll-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosisRespir Investig2015535232241
   PubMedGoogle Scholar
• HarariSCaminatiAIdiopathic pulmonary fibrosis: from clinical trials to real-life experiencesEur Respir Rev20152413742042726324803
   PubMedGoogle Scholar
• CostabelUAlberaCBradfordWZAnalysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosisSarcoidosis Vasc Diffuse Lung Dis201431319820525363219
   PubMed Web of Science ®Google Scholar
• LancasterLAlberaCBradfordWZSafety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsBMJ Open Respir Res201631e000105 eCollection 2016
   PubMed Web of Science ®Google Scholar
• NathanSDAlberaCBradfordWZEffect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisThorax201671542943526968970
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research NetworkMartinezFJde AndradeJAAnstromKJRandomized trial of acetylcysteine in idiopathic pulmonary fibrosisN Engl J Med20143702093210124836309
   PubMed Web of Science ®Google Scholar
• BehrJBendstrupECrestaniBSafety and tolerability of acetyl-cysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trialLancet Respir Med20164644545327161257
   PubMed Web of Science ®Google Scholar
• KingCSNathanSDPractical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosisCurr Opin Pulm Med201521547948926164298
   PubMed Web of Science ®Google Scholar
• SpagnoloPMaherTMRicheldiLIdiopathic pulmonary fibrosis: recent advances on pharmacological therapyPharmacol Ther2015152182725946646
   PubMed Web of Science ®Google Scholar
• Esbriet (pirfenidone) [prescribing information]South San Francisco, CAGenentech USA2015
   Google Scholar
• JiangCHuangHLiuJWangYLuZXuZAdverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trialsPLoS One2012710e4702423056564
   PubMed Web of Science ®Google Scholar
• OltmannsUKahnNPalmowskiKPirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseasesRespiration201488319920725115833
   PubMed Web of Science ®Google Scholar
• MilgerKKneidingerNNeurohrCReichenbergerFBehrJSwitching to nintedanib after discontinuation of pirfenidone due to adverse events in IPFEur Respir J20154641217122126341986
   PubMed Web of Science ®Google Scholar
• RaghuGRochwergBZhangYAmerican Thoracic SocietyEuropean Respiratory societyJapanese Respiratory SocietyLatin American Thoracic AssociationAn Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guidelineAm J Respir Crit Care Med20151922e3e1926177183
   PubMed Web of Science ®Google Scholar
• WeillDBendenCCorrisPAA consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung TransplantationJ Heart Lung Transplant201534111525085497
   PubMed Web of Science ®Google Scholar
• CollardHRRyersonCJCorteTJAcute exacerbations of idiopathic pulmonary fibrosis. An international working group reportAm J Respir Crit Care Med20072016194265275
   Google Scholar
• MaherTMWhyteMKHoylesRKDevelopment of a consensus statement for the definition, diagnosis, and treatment of acute exacer-bations of idiopathic pulmonary fibrosis using the Delphi techniqueAdv Ther2015321092994326498943
   PubMed Web of Science ®Google Scholar
• KhannaDAlberaCFischerAAn open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trialJ Rheumatol20164391672167927370878
   PubMed Web of Science ®Google Scholar
• MeyerKCDiagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantationExpert Rev Respir Med20161059960226950825
   PubMed Web of Science ®Google Scholar
• HeySPKesselheimASCountering imprecision in precision medicineScience201635344844927471295
   PubMed Web of Science ®Google Scholar
• BrownellRKaminskiNWoodruffPGPrecision medicine: the new frontier in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2016193111213121826991475
   PubMed Web of Science ®Google Scholar
• LoehBDrakopanagiotakisFBandelliGPIntraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2015191111011325551350
   PubMed Web of Science ®Google Scholar